---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-160789"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:29:13.737609+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics amends EVP Kristina Masson's employment agreement with $382,200 base salary

## Summary
- Amended employment agreement with Kristina M. Masson, EVP of Business Operations and board member, effective June 1, 2023.
- Base salary set at $382,200; target annual bonus up to 40% of salary.
- Separate Swedish employment agreement for role as President/CEO of Acrivon AB with base salary $163,800.
- Severance: if terminated without cause or for good reason, 9 months base salary plus pro-rata bonus; enhanced terms after change of control.

## SEC filing metadata
- accession: 0001193125-23-160789
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523160789/0001193125-23-160789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523160789/d508323d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-160789
- JSON: https://secwatch.observer/filing/0001193125-23-160789.json
- Plain text: https://secwatch.observer/filing/0001193125-23-160789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.